Ceruletide

ArtNr	HY-A0190-5mg
Hersteller	MedChem Express
CAS-Nr.	17650-98-5
Menge	5 mg
Quantity options	100 ug 10mM*1 mL 10mg 1 mg 500 ug 500 ug x 2 5 mg
Kategorie	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer
Typ	Inhibitors
Specific against	other
Purity	99.96
Formula	C58H73N13O21S2
Citations	[1]Vincent ME, et al. Pharmacology, clinical uses, and adverse effects of ceruletide, a cholecystokinetic agent. Pharmacotherapy. 1982 Jul-Aug;2(4):223-34.<br/>[2]Steinle AU, et al. NF-kappaB/Rel activation in cerulein pancreatitis. Gastroenterology. 1999 Feb;116(2):420-30.<br/>[3]Bridger N, et al. Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8.<br/>[4]Zarrindast MR, et al. Effects of cholecystokinin receptor agonist and antagonists on morphin dependence in mice. Pharmacol Toxicol. 1995 Dec;77(6):360-4.<br/>[5]Ke-You Zhang, et al. Chemically Induced Models of Pancreatitis. 2022. Pancreapedia: Exocrine Pancreas Knowledge Base, DOI: 10.3998/panc.2022.01<br/>[6]Wu Z, et al. Dopamine D2 Receptor Signaling Attenuates Acinar Cell Necroptosis in Acute Pancreatitis through the Cathepsin B/TFAM/ROS Pathway. Oxid Med Cell Longev. 2022 Jul 26;2022:4499219. <br/>[7]Kong L, et al. Sitagliptin activates the p62-Keap1-Nrf2 signalling pathway to alleviate oxidative stress and excessive autophagy in severe acute pancreatitis-related acute lung injury. Cell Death Dis. 2021 Oct 11;12(10):928. <br/>[8]Malla SR, et al. Early trypsin activation develops independently of autophagy in caerulein-induced pancreatitis in mice. Cell Mol Life Sci. 2020 May;77(9):1811-1825.<br/>[9]Lin Y, et al. Neddylation pathway alleviates chronic pancreatitis by reducing HIF1α-CCL5-dependent macrophage infiltration. Cell Death Dis. 2021 Mar 15;12(3):273.
Smiles	O=C(N[C@@H](CCSC)C(N[C@@H](CC(O)=O)C(N[C@H](C(N)=O)CC1=CC=CC=C1)=O)=O)[C@@H](NC(CNC([C@@]([C@H](O)C)([H])NC([C@@H](NC([C@H](CC(O)=O)NC([C@H](CCC(N)=O)NC([C@H](CC2)NC2=O)=O)=O)=O)CC3=CC=C(OS(=O)(O)=O)C=C3)=O)=O)=O)CC4=CNC5=C4C=CC=C5
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Caerulein; Cerulein; FI-6934
Lieferbar
Product Description	Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts[1].
StorageTemperature	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Shipping	Blue Ice
Manufacturers Applications	COVID-19-immunoregulation
MolecularWeight	1352.41
Clinical Information	Launched
Manufacturers Research Area	Metabolic Disease; Cardiovascular Disease; Endocrinology
Solubility	DMF : 16.67 mg/mL (ultrasonic)\|DMSO : 100 mg/mL (ultrasonic)\|H2O : 2.5 mg/mL (ultrasonic)
Target	Cholecystokinin Receptor
Manufacturers Target	Cholecystokinin Receptor
Manufacturers Pathway	GPCR/G Protein; Neuronal Signaling
Manufacturers Product type	Peptides

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkdatenblatt anfordern

HY-A0190-5mg-safety-datasheet.pdf